Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Butler

Neurology Stratford, CT Medical Doctor

NPI 1508802935 CMS profile 204610

2590 Main St, Stratford, CT 06615

Open in the dashboard

General payments

$6,187

364 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Butler of Stratford, CT is reported in the CMS Open Payments database as having received $6,187 across 364 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $330 21
2024 General $280 19
2023 General $228 19
2022 General $638 44
2021 General $1,811 107
2020 General $1,024 58
2019 General $1,876 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Butler
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to James Butler were reported at $330. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year James Butler Neurology median Middle half National median
2019 $1,876 $474 $118–$2,177 $163
2020 $1,024 $367 $82–$2,309 $114
2021 $1,811 $438 $104–$2,547 $132
2022 $638 $442 $103–$2,388 $149
2023 $228 $464 $119–$2,312 $160
2024 $280 $468 $119–$2,323 $164
2025 $330 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,385 108 payments
  2. AbbVie, Inc. $642 37 payments
  3. Biogen, Inc. $451 27 payments
  4. UCB, Inc. $384 17 payments
  5. Alexion Pharmaceuticals, Inc. $323 20 payments
  6. ACADIA Pharmaceuticals Inc $319 19 payments
  7. Lilly USA, LLC $254 10 payments
  8. Teva Pharmaceuticals USA, Inc. $238 15 payments
  9. Genzyme Corporation $205 7 payments
  10. Genentech USA, Inc. $168 4 payments
  11. Other $1,818 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,146 361 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41 3 payments
Products named General payments · program years 2019–2025
  1. KESIMPTA Neurology $767 56 payments
  2. UBRELVY $402 24 payments
  3. KESIMPTA Neuroscience $374 33 payments
  4. Soliris $323 20 payments
  5. NUPLAZID $319 19 payments
  6. MAYZENT $269 30 payments
  7. Briviact $235 9 payments
  8. TECFIDERA $232 15 payments
  9. NURTEC ODT $202 11 payments
  10. VUMERITY $198 11 payments
  11. Other $3,095 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Psychiatry & Neurology: 100

Drug cost

$116

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Donepezil Hcl Generic 13 $116

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $231
$231 — —
QULIPTA
  • AbbVie, Inc. $29
$29 — —
RYTARY
  • Amneal Pharmaceuticals LLC $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

364 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record